SCHEMBL21135750

SCHEMBL21135750

CC(C)(C)OC(=O)NC[C@@]1(c2cc(F)ccc2F)C[C@H]1CO

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 2/20 0.38
DPP9 Q86TI2 2/20 0.38
PSEN1 P49768 6/20 0.36
PSEN2 P49810 5/20 0.36
APH1B Q8WW43 5/20 0.36
NCSTN Q92542 5/20 0.36
APH1A Q96BI3 5/20 0.36
PSENEN Q9NZ42 5/20 0.36
GPR119 Q8TDV5 1/20 0.36
AKR1B1 P15121 2/20 0.35
DRD2 P14416 2/20 0.35
APP P05067 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
SLC6A2 P23975 1/20 0.35
HRH2 P25021 1/20 0.35
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29891320 1.00 DPP8 (0.38) DPP8DPP9PSEN1PSEN2APH1B
SCHEMBL22766314 0.90 IDO1 (0.39) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL20001962 0.89 AAK1 (0.39) CTSSCTSK
SCHEMBL23455167 0.83 AKR1B1 (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL23455193 0.83 AKR1B1 (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL20005977 0.82 HCRTR2 (0.35) DPP8DPP9DRD2GRM2HCRTR2
SCHEMBL20005716 0.82 HCRTR2 (0.35) DPP8DPP9DRD2GRM2HCRTR2
SCHEMBL13720547 0.77 IDO1 (0.41) DRD2SIGMAR1CTSSCTSK
SCHEMBL22917996 0.75 SLC6A3 (0.48) DRD2SLC6A3
SCHEMBL13698145 0.75 SLC6A3 (0.48) DRD2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138795-A1 DOPAMINE-B-HYDROXYLASE INHIBITORS BIAL PORTELA & CA SA (PT) 2023-05-04 US disclosed
US-20230138795-A1 DOPAMINE-B-HYDROXYLASE INHIBITORS BIAL PORTELA & CA SA (PT) 2023-05-04 US disclosed
US-20210171528-A1 DOPAMINE-B-HYDROXYLASE INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2021-06-10 US disclosed
WO-2019112457-A1 DOPAMINE-Β-HYDROXYLASE INHIBITORS BIAL - PORTELA & Cª, S.A. (PT) 2019-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138795-A1 DOPAMINE-B-HYDROXYLASE INHIBITORS DBH, MAOB, COMT DPP8 1771/4885DPP9 1694/4885PSEN1 855/4885
US-20210171528-A1 DOPAMINE-B-HYDROXYLASE INHIBITORS DBH, MAOB, COMT DPP8 1635/4885DPP9 1499/4885PSEN1 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.